This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Wall Street Rejoices as Regulators Agree to Modify Capital Plan
by Nikita Kataruka
JPMorgan (JPM), BofA (BAC), Fifth Third (FITB), Regions Financial (RF) and other banks covered under the proposed capital plan can take a breather as the Fed signals modifications to the plan.
FDIC-Insured Banks' Q4 Earnings Down on Non-Recurring Charge
by Swayta Shah
The FDIC-Insured banks' (like JPM, BAC, C & WFC) Q4 earnings are hurt by rising funding costs, an increase in non-interest expenses and poor asset quality. Yet, higher rates, changing revenue mix and decent loan demand offer some support.
BofA (BAC) Expects Higher IB Fees, Flat Markets Revenues in Q1
by Zacks Equity Research
BofA (BAC) projects IB revenues to improve in Q1 but markets revenues to remain relatively stable. Also, the company expects NII to be at the upper end of the $13.9-$4 billion range.
Citigroup (C) Expects Higher IB Fees in Q1, Lower Market Revenues
by Zacks Equity Research
Citigroup (C) expects investment banking fees to sequentially improve in the low-teens range in the first quarter of 2024. However, market revenues are expected to reduce by 8%-12% in the first quarter.
PNC Financial (PNC) to Incur Additional $130M in FDIC Fees in Q1
by Zacks Equity Research
Owing to a revision in FDIC's estimated losses, PNC Financial (PNC) expects to incur an additional $130 million in assessment fees on a pre-tax basis in the first quarter.
JPMorgan Chase & Co. (JPM) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to JPMorgan Chase & Co. (JPM). This makes it worthwhile to examine what the stock has in store.
Capital One (COF) Gets Victory in Lawsuit Filed by Cardholders
by Zacks Equity Research
A U.S. district judge dismisses lawsuit filed by cardholders against Capital One (COF), citing overcharging of customers on foreign currency related transactions.
Should Vanguard Value ETF (VTV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VTV
JPMorgan Chase & Co. (JPM) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the latest trading session, JPMorgan Chase & Co. (JPM) closed at $186.68, marking a +0.75% move from the previous day.
Regionals in Flux: Powell's Insights & the Small Bank Challenge
by Andrew Rocco
Investors should avoid regional banking stocks with Commercial Real Estate Exposure.
Should Schwab U.S. Large-Cap Value ETF (SCHV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHV
Cullen/Frost (CFR) Rides On Organic Growth Amid Cost Woes
by Zacks Equity Research
Cullen/Frost's (CFR) strong loan book, solid NII and steady capital distribution activities are positives. However, the company is affected by mounting costs and an undiversified loan portfolio.
New York Community (NYCB) Q4 Loss Widens on Goodwill Impairment
by Zacks Equity Research
New York Community (NYCB) announces an increase in 4Q23 earnings loss to $2.7 billion due to a $2.4-bilion goodwill impairment charge. It also identifies weaknesses in its loan review process.
Morgan Stanley (MS) Expands in UAE With Office in Abu Dhabi
by Zacks Equity Research
Morgan Stanley (MS) establishes an office in Abu Dhabi to expand its footprint in the Middle East. The move is in line with its efforts to gain business opportunities from the capital markets in the region.
JPMorgan (JPM) Picks Firms for Hong Kong, Taiwan Custody Business
by Zacks Equity Research
JPMorgan (JPM) selects HSBC and Standard Chartered to run its custody business in Hong Kong and Taiwan.
Should iShares Russell 1000 Value ETF (IWD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWD
JPMorgan (JPM) Close to Forming Private Credit Partnership
by Zacks Equity Research
JPMorgan (JPM) is in advanced talks with FS Investments and Octagon Credit Investors to form a partnership to expand into the rapidly growing private credit space.
Brokers Suggest Investing in JPMorgan Chase & Co. (JPM): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), JPMorgan Chase & Co. (JPM) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
JPMorgan Chase & Co. (JPM) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
JPMorgan Chase & Co. (JPM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Fifth Third (FITB) Rides on Organic Growth Amid Cost Woes
by Zacks Equity Research
Diversified revenue sources, along with a rise in loans and deposits, are likely to support Fifth Third (FITB). However, escalating expenses and major exposure to commercial loans are headwinds.
JPMorgan (JPM) Expects Y/Y Decline in Q1 Trading Revenues
by Zacks Equity Research
JPMorgan (JPM) expects markets revenues in the first quarter of 2024 to decline 5-10% from the prior-year quarter.
4 Reasons Why Northern Trust (NTRS) Stock is a Must-Buy Now
by Zacks Equity Research
Northern Trust (NTRS) seems to be an attractive investment option now, supported by decent top-line growth and prudent expense management.
The Zacks Analyst Blog Highlights JPMorgan Chase, Salesforce, Vertex Pharmaceuticals, Palo Alto Networks and The Williams Companies
by Zacks Equity Research
JPMorgan Chase, Salesforce, Vertex Pharmaceuticals, Palo Alto Networks and The Williams Companies are part of the Zacks top Analyst Blog.
JPMorgan Chase & Co. (JPM) Stock Moves -0.34%: What You Should Know
by Zacks Equity Research
In the most recent trading session, JPMorgan Chase & Co. (JPM) closed at $183.36, indicating a -0.34% shift from the previous trading day.
Top Stock Reports for JPMorgan Chase, Salesforce & Vertex Pharmaceuticals
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Salesforce, Inc. (CRM) and Vertex Pharmaceuticals Incorporated (VRTX).